---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-118952"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2026-10-27T10:06:18+00:00"
generated_at: "2026-10-27T10:10:12.122451+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aclaris ATI-052 Phase 1b hits: 45% placebo-adjusted EASI in AD, 59% FeNO cut in asthma

## Summary
- AD: ATI-052 480 mg weekly cut EASI 58% vs 13% placebo at day 57, a 45% placebo-adjusted mean improvement; EASI-50 was 78% placebo-adjusted.
- Itch: PP-NRS improved 43% placebo-adjusted at day 57 (38% active vs 5% worsening placebo); 33% achieved placebo-adjusted PP-NRS4 response.
- Asthma: single 480 mg dose cut FeNO 59% (45 ppb) at day 15 vs 15% placebo; 58% reached FeNO ≤25 ppb; FEV1 improved 200 mL placebo-adjusted.
- Safety: no Grade 3/4 TEAEs, no discontinuations, no conjunctivitis; injection-site reactions transient and mostly Grade 1.
- Aclaris will prioritize ATI-052 in eosinophilic esophagitis, planning a Phase 2b trial in early 2027; preliminary cash was $204.6M at Sept 30, 2026.

## SEC filing metadata
- accession: 0001104659-26-118952
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2026-10-27T10:06:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000110465926118952/0001104659-26-118952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000110465926118952/acrs-20261027x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-118952
- JSON: https://secwatch.observer/filing/0001104659-26-118952.json
- Plain text: https://secwatch.observer/filing/0001104659-26-118952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.